Biotechnology Stock News
Categories
- All
- Editor's Picks
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus Research Biotechnology
Axsome Therapeutics Inc (AXSM) Q2 2024 Earnings Call Transcript Highlights: Strong Product Sales and Strategic Developments Amid Rising Expenses
Axsome Therapeutics Inc (AXSM) reports significant revenue growth and strategic advancements, despite increased expenses and net loss. Aug 06, 2024
GuruFocus Research Biotechnology
BioCryst Pharmaceuticals Inc (BCRX) Q2 2024 Earnings Call Transcript Highlights: Strong ORLADEYO Performance and Increased Revenue Guidance
BioCryst Pharmaceuticals Inc (BCRX) reports robust Q2 results with significant revenue growth and optimistic future projections. Aug 06, 2024
GuruFocus Research Biotechnology
Theravance Biopharma Inc (TBPH) Q2 2024 Earnings Call Transcript Highlights: Strong Demand Amid Pricing Challenges
Theravance Biopharma Inc (TBPH) reports robust hospital doses and customer demand for YUPELRI, but faces pricing pressures and delays in key studies. Aug 06, 2024